Unfortunately, many physicians are not aware of new developments in the current understanding of thyroid hormone transport, which has resulted in an overreliance on the sole use of standard thyroid blood tests (e.g., thyroid-stimulating hormone (TSH) and T4 levels) to determine the presence or absence of hypothyroidism
Consistent with a proposed role in Ca 2+ regulation, we observed MS4A15 localization to the ER (Supplementary Fig
Conclusion: Its About Choices, Not Obligations When we look at weight loss through this lens, we realize that the journey isnt only about reaching the goal but also about building habits to sustain that goal
Developed by Teva Pharmaceuticals, Uzedy is a once-monthly extended-release injectable suspension for adults with BD-I, used either as monotherapy or adjunctive therapy to lithium or valproate
To come up with our picks for the best fat burners (and to ensure that were safely making our recommendations), we teamed up with a registered dietitian to test and evaluate over 140 different supplements
The market is being reshaped by 6 forces: Market size: $94B today $216B+ by 2035 (8.8% CAGR) Oral GLP-1s just got FDA approval eliminating the needle barrier for millions WHO officially recommends GLP-1s for long-term obesity treatment (Dec 2025) Novo Nordisk slashed Ozempic/Wegovy prices by up to 70% unlocking mass adoption Next-gen tri-agonists (retatrutide) showing 28.7% weight loss in trials Only ~7% diabetes penetration and ~2% obesity penetration the growth runway is massive The ripple effects extend far beyond pharma: Food & beverage: $30$55B annual revenue at risk as GLP-1 users cut calories by 21% Employers: 77% of large companies say managing GLP-1 costs is a top priority Eli Lilly became the first pharma company to surpass $1 trillion market cap ~150 GLP-1 drugs now in development globally 2530 million Americans projected on GLP-1 therapy by 2030 The question isnt whether GLP-1s will reshape global healthcare
